Stiolto Respimat

DEVICE4 trials

Sponsors

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Boehringer Ingelheim

Conditions

Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic Obstructive

Phase 4

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

CompletedNCT02845752

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterChronic Obstructive Pulmonary Disease

Start: 2017-03-01End: 2018-08-06Updated: 2020-08-06

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

CompletedNCT03265145

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2017-09-20End: 2020-09-30Updated: 2022-06-14

Unknown Phase

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

CompletedNCT05127304

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2021-02-26End: 2022-02-03Updated: 2023-11-13

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT05169424

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2021-12-17End: 2021-12-27Updated: 2023-10-19

Related Papers

Clinical and Economic Evaluation of Fluticasone Furoate/Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol Therapy in Maintenance Treatment–Naive Patients with COPD in the US

International Journal of COPD2025-02-011 citations

Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol

Journal of Managed Care & Specialty Pharmacy2023-05-036 citations

A randomized, crossover, placebo controlled, double-blind trial of the effects of tiotropium-olodaterol on neuromuscular performance during exercise in COPD.

2022-03-245 citations

A Randomized, Placebo Controlled, Double‐Blind, Crossover Trial of the Effect of Stiolto Respimat on Neuromuscular Performance During Cycling in COPD

The FASEB Journal2020-04-01